For prostate cancer, study identifies how common mutation makes good cells go bad

August 3, 2018 by Tom Ulrich, Broad Institute of MIT and Harvard
Credit: CC0 Public Domain

In more than half of all prostate tumors, two genes—one for a transcription factor called ERG, the other a testosterone-triggered gene called TMPRSS2—become fused together, resulting in excess ERG expression. The TMPRSS2-ERG protein pushes prostate cells to become cancerous, but precisely how it does so, and what can be done about it, have been unclear.

In a paper in Molecular Cell, a research team led by Gabriel Sandoval, John Pulice, Broad institute member William Hahn, and institute member and Epigenomics Program co-director Cigall Kadoch (all also at the Dana-Farber Cancer Institute) showed that the fused protein engages in an act of molecular piracy, roping a cellular machine called the BAF complex into helping it boot up a gene expression program that would otherwise be silent in normal prostate . This, they found, encourages prostate cells' transformation into cells, and may provide a new opportunity for prostate cancer drug development.

Transcription factors like ERG perform a variety of tasks that help a cell express the right at the right time. Cells are normally quite picky about which transcription factors they use, expressing certain ones only at certain times during their development and growth. Normal prostate cells, for instance, neither produce nor use ERG, but the TMPRSS2-ERG gene fusion pushes these cells to produce the factor constantly.

To understand the consequences of this untimely activity, the team joined several collaborators, including members of the Broad's Cancer Program and Proteomics Platform, to find out which proteins partner with the fused ERG factor in .

High up on the resulting list were several members of BAF, a complex of proteins that work together to open tightly packed DNA for transcription. Using a mix of cell line and organoid models of prostate cancer, the team found that the overexpressed TMPRSS2-ERG protein retargets BAF complexes, forcing them to open up regions of ' DNA they would otherwise not, turning on normally inactive genes, and driving the cells to turn cancerous.

The team also noted that ERG relies on BAF complexes to do its dirty work; in their experiments, suppressing members of BAF shut down the gene program activated by TMPRSS2-ERG. This may present an opportunity: a drug that interferes with BAF and TMPRSS2-ERG's interactions, they think, could alter gene expression in powerfully therapeutic ways.

This is not the first case of BAF complex hijacking that Kadoch's lab has come across. Previously they reported that another fused protein, called SS18-SSX, similarly commandeers BAF complexes in a rare cancer called synovial sarcoma, and that the EWS-FLI1 fusion protein retargets BAF complexes in another tumor called Ewing sarcoma.

Explore further: Team defines the mechanisms of action of key genetic abnormality in Ewing sarcoma

More information: Gabriel J. Sandoval et al. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis, Molecular Cell (2018). DOI: 10.1016/j.molcel.2018.06.040

Matthew J. McBride et al. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma, Cancer Cell (2018). DOI: 10.1016/j.ccell.2018.05.002

Gaylor Boulay et al. Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain, Cell (2017). DOI: 10.1016/j.cell.2017.07.036

Related Stories

Team defines the mechanisms of action of key genetic abnormality in Ewing sarcoma

August 2, 2018
A Massachusetts General Hospital (MGH) research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma—the second most common bone cancer in children and young adults—unleashes ...

Study may help explain racial disparities in prostate cancer

May 9, 2018
New research published in Molecular Oncology may help explain why African American men are at a higher risk of being diagnosed with prostate cancer and a higher risk of dying from the disease compared with European American ...

Common genetic fusion event may be associated with low-risk prostate cancer

November 10, 2017
Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a ...

Proteins reveal new mechanisms in prostate cancer

March 22, 2018
A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were ...

Prostate cells undergo 'reprogramming' to form tumors, study finds

October 12, 2015
Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth.

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.